A new potential therapeutic target against Covid-19

7 août 2020

A study conducted by researchers and from Gustave Roussy, Assistance Publique – Hôpitaux de Paris AP-HP, Inserm, Université Paris-Saclay and Université de Paris, in collaboration with teams from Singapore, China and Israel, reveals that patients with severe form of Covid-19 have a deficit in the innate immunity of myeloid cells (fraction of white blood cells such as polynuclear neutrophils, monocytes) functions, associated with a very high level of calprotectin, a pro-inflammatory protein from the alarmin family, in the blood.

Published in Cell, these results make it possible to propose a diagnostic test capable of rapidly identifying patients at risk of developing a severe form of the disease and open the way to an unprecedented therapeutic approach: blocking the calprotectin receptor, a pro-inflammatory protein from the alarmin family.

Press release

 Prism est un partenariat unique entre

Label

Centre National de Médecine de Précision en Oncologie

Nous contacter

Prism  IHU-B

Bâtiment de médecine moléculaire

32 Rue Camille Desmoulins

94800 Villejuif

Tél. +33(0)1 42 11 00 00

info -at- prism.center

Liens

Presse

Rejoindre nos équipes

Appels à projets

Accessibilité

Les cookies

Mentions légales

Réseaux sociaux